Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses

Expert Opinion on Biological Therapy

Volumn 9, Issue 3, 2009, Pages 355-368

  Prabakaran, Ponraj ^a,b   Zhu, Zhongyu ^a,c   Xiao, Xiaodong ^a   Biragyn, Arya ^a,d   Dimitrov, Antony S ^a,e,f   Broder, Christopher C ^a,f   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e Profectus BioSciences Inc   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Antibody; Hendra virus; Nipah virus; SARS CoV; Therapeutics; Vaccines

Indexed keywords

DNA VACCINE; HEV SG VACCINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY 80R; IMMUNOGLOBULIN G1 ANTIBODY CR3014; MONOCLONAL ANTIBODY 201; MONOCLONAL ANTIBODY 68; MONOCLONAL ANTIBODY ACE2; MONOCLONAL ANTIBODY B1; MONOCLONAL ANTIBODY CR3022; MONOCLONAL ANTIBODY F26G18; MONOCLONAL ANTIBODY F26G19; MONOCLONAL ANTIBODY M101; MONOCLONAL ANTIBODY M102; MONOCLONAL ANTIBODY M102.4; MONOCLONAL ANTIBODY M106; MONOCLONAL ANTIBODY M396; MONOCLONAL ANTIBODY S215.13; MONOCLONAL ANTIBODY S230.15; MONOCLONAL ANTIBODY S3.1; NEUTRALIZING ANTIBODY; NIV SG VACCINE; PEPTIDE VACCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VITRONECTIN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL RESISTANCE; CROSS REACTION; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HENDRA VIRUS; HUMAN; INFECTION PREVENTION; NIPAH VIRUS; NONHUMAN; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PROTEIN TARGETING; RECEPTOR AFFINITY; REVIEW; SARS CORONAVIRUS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TREATMENT OUTCOME; VIRUS ENTRY; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; CORONAVIRUS; IMMUNOLOGY;

CORONAVIRUS; HENDRA VIRUS; NIPAH VIRUS; SARS CORONAVIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CORONAVIRUS; HENDRA VIRUS; HUMANS; NIPAH VIRUS; SARS VIRUS;

EID: 65549111385     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902763755     Document Type: Review

References (117)

1. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004;2:109-22 • A review on virus entry focusing on molecular mechanisms and applications to vaccines and inhibitors, including antibodies.
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2:695-703 •• An excellent review on antibody therapy.
3. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999;93:5-15 (Pubitemid 29459957)
4. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-161
5. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-1702 (Pubitemid 24250712)
6. Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microb Infect 2000;2:701-708 (Pubitemid 30412581)
7. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57-77 •• An excellent review on antibodies for prevention and treatment of viral diseases.
8. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004;25:306-310
9. DesJardin JA, Snydman DR. Antiviral immunotherapy - a review of current status. Biodrugs 1998;9:487-507 (Pubitemid 28267158)
10. Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997;64:1847-1850 (Pubitemid 28041728)
11. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-523 (Pubitemid 19203877)
12. Kerr JR, Cunniffe VS, Kelleher P, et al. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis 2003;36:e100-6
13. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin - a report of eight patients. Am J Hematol 1999;61:16-20 (Pubitemid 29218172)
14. Clayton AJ. Lassa immune serum. Bull World Health Organ 1977;55:435-439 (Pubitemid 8222030)
15. Krasnianskii VP, Gradoboev VN, Borisevich IV, et al. Development and study of properties of immunoglobulins against Lassa fever. Vopr Virusol 1997;42:168-171 (Pubitemid 127519768)
16. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001;7:759 (Pubitemid 32845276)
17. Hamdan A, Green P, Mendelson E, et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002;4:160-162 (Pubitemid 35364781)
18. Pasic S, Jankovic B, Abinun M, Kanjuh B. Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak. Pediatr Infect Dis J 1997;16:718-720 (Pubitemid 27300715)
19. Rotbart HA, O'Connell JF, McKinlay MA. Treatment of human enterovirus infections. Antiviral Res 1998;38:1-14 (Pubitemid 28182284)
20. Masci S, De Simone C, Famularo G, et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol 1995;17:33-47
21. Vassilenko SM, Vassilev TL, Bozadjiev LG, et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990;335:791-792 (Pubitemid 20106716)
22. Enria DA, Briggiler AM, Fernandez NJ, et al. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2:255-256 (Pubitemid 14057078)
23. Ali MB. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J 2003;9:391-392 (Pubitemid 37247868)
24. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9:309 (Pubitemid 36987731)
25. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;92:1195-1199
26. Jablonowski H, Sander O, Willers R, et al. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Investig 1994;72:220-224
27. Olopoenia L, Young M, White D, et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 1997;89:543-547 (Pubitemid 127459610)
28. Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002;16:1391-1400 (Pubitemid 34722071)
29. Dezube BJ, Proper J, Zhang J, et al. A passive immunotherapy, PEHRG214, in patients infected with human immunodeficiency virus: a Phase I study. J Infect Dis 2003;187:500-503 (Pubitemid 36184592)
30. Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992;6:1235-1247
31. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005;350:126-44 • Perhaps the most potent antibody of potential clinical use against respiratory syncytial virus is described. (Pubitemid 40804737)
32. Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23:707-712 (Pubitemid 39063284)
33. Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005;79:3962-3968
34. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66 • The first identification of SARS coronavirus.
35. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-1325 (Pubitemid 36514862)
36. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76 • The first identification of SARS coronavirus.
37. Holmes KV. SARS-associated coronavirus. N Engl J Med 2003;348:1948-1951 (Pubitemid 36569982)
38. Hsueh PR, Huang LM, Chen PJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004;10:1062-1066 (Pubitemid 40044978)
39. Nie Y, Wang G, Shi X, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004;190:1119-1126 (Pubitemid 39186799)
40. Shi Y, Wan Z, Li L, et al. Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol 2004;31:66-68 (Pubitemid 39024387)
41. Han DP, Kim HG, Kim YB, et al. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004;326:140-149 (Pubitemid 38943013)
42. Guo JP, Petric M, Campbell W, McGeer PL. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 2004;324:251-256 (Pubitemid 38797843)
43. Hofmann H, Hattermann K, Marzi A, et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004;78:6134-6142 (Pubitemid 38715911)
44. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004;78:3572-3577 (Pubitemid 38568299)
45. Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79:503-511 (Pubitemid 39648403)
46. Mcauliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 2004;330:8-15 (Pubitemid 39446562)
47. Zhou T, Wang H, Luo D, et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 2004;78:7217-7226 (Pubitemid 38781560)
48. Zhang H, Wang G, Li J, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938-6945 (Pubitemid 38781532)
49. Yao YX, Ren J, Heinen P, et al. Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis 2004;190:91-98 (Pubitemid 38858408)
50. Zeng F, Chow KY, Hon CC, et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun 2004;315:1134-1139 (Pubitemid 38249421)
51. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-564 (Pubitemid 38480539)
52. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004;101:6641-6646 (Pubitemid 38586027)
53. Qu D, Zheng B, Yao X, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005;23:924-931 (Pubitemid 39643181)
54. Xiong S, Wang YF, Zhang MY, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 2004;95:139-143 (Pubitemid 39237658)
55. He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004;173:4050-4057 (Pubitemid 39280769)
56. Takasuka N, Fujii H, Takahashi Y, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004;16:1423-1430 (Pubitemid 39341555)
57. Tang L, Zhu Q, Qin E, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 2004;23:391-394 (Pubitemid 38850386)
58. Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9809 (Pubitemid 38869317)
59. He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004;325:445-452 (Pubitemid 39458016)
60. Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004;85:3109-3113 (Pubitemid 39360055)
61. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78:12672-12676 (Pubitemid 39458786)
62. Weingartl HM, Copps J, Drebot MA, et al. Susceptibility of pigs and chickens to SARS coronavirus. Emerg Infect Dis 2004;10:179-184 (Pubitemid 38176952)
63. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-1896 (Pubitemid 37518507)
64. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004;363:2122-2127- (Pubitemid 38844152)
65. Xiao X, Dimitrov DS. The SARS-CoV S glycoprotein. Cell Mol Life Sci 2004;61:2428-2430 (Pubitemid 39586507)
66. Berry JD, Jones S, Drebot MA, et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods 2004;120:87-96 (Pubitemid 38968659)
67. Gubbins MJ, Plummer FA, Yuan XY, et al. Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. Mol Immunol 2005;42:125-136 (Pubitemid 39360934)
68. Murray K, Selleck P, Hooper P, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995;268:94-97
69. Lee KE, Umapathi T, Tan CB, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol 1999;46:428-432 (Pubitemid 29416285)
70. Lim CC, Sitoh YY, Hui F, et al. Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease. AJNR Am J Neuroradiol 2000;21:455-461 (Pubitemid 30149335)
71. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999;354:1257-1259 (Pubitemid 29469355)
72. Chew MH, Arguin PM, Shay DK, et al. Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis 2000;181:1760-1763 (Pubitemid 30387772)
73. Chua KB, Lam SK, Tan CT, et al. High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. Ann Neurol 2000;48:802-805 (Pubitemid 30823234)
74. Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000;342:1229-1235 (Pubitemid 30235951)
75. Update: outbreak of Nipah virus - Malaysia and Singapore, 1999. MMWR Morb Mortal Wkly Rep 1999;48:335-337
76. Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000;288:1432-1435 (Pubitemid 30366331)
77. Eaton BT. Introduction to Current focus on Hendra and Nipah viruses. Microb Infect 2001;3:277-278 (Pubitemid 32385776)
78. Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006;4:23-35 (Pubitemid 43135284)
79. Bossart KN, Broder CC. Developments towards effective treatments for Nipah and Hendra virus infection. Expert Rev Anti Infect Ther 2006;4:43-55
80. Bossart KN, McEachern JA, Hickey AC, et al. Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods 2007;142:29-40 (Pubitemid 46613909)
81. Guillaume V, Contamin H, Loth P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004;78:834-840 (Pubitemid 38067605)
82. Bossart KN, Crameri G, Dimitrov AS, et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 2005;79:6690-6702 (Pubitemid 40677300)
83. Guillaume V, Contamin H, Loth P, et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 2006;80:1972-1978 (Pubitemid 43228737)
84. Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther 2005;7:151-156 (Pubitemid 40514685)
85. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871-5 •• A new efficient method for identification of human monoclonal antibodies directly using B cells from human and development of very potent neutralizers of severe acute respiratory syndrome coronavirus (SCV) is described. (Pubitemid 39070862)
86. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005;102:797-801 • A report of virus entry enhancement of SCV S RBD specific antibody in vitro.
87. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101:2536-2541 (Pubitemid 38269346)
88. Hwang WC, Lin YQ, Santelli E, et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006;281:34610-34616 (Pubitemid 46036667)
89. Sui J, Li W, Roberts A, et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005;79:5900-5906 (Pubitemid 40617195)
90. ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004;363:2139-41 • A demonstration of the efficacy of an anti-SCV human monoclonal antibody in the ferret model of SCV infections.
91. van den Brink EN, ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005;79:1635-1644 (Pubitemid 40459110)
92. Ter MJ, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006;3:e237. Published online July 4 2006, doi:10.1371/journal.pmed. 0030237 (Pubitemid 44125993)
93. Greenough TC, Babcock GJ, Roberts A, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005;191:507-514 (Pubitemid 40216665)
94. Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006;281:15829-36 •• Structural insights into m396's broad neutralizing activity against various SCV isolates are described. (Pubitemid 43848473)
95. Xiao X, Chakraborti S, Dimitrov AS, et al. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-1164 (Pubitemid 37490937)
96. Chakraborti S, Prabakaran P, Xiao X, Dimitrov DS. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2005;2:73. Published online August 25 2005, doi:10.1186/1743-422X-2-73 (Pubitemid 41379837)
97. Wong SK, Li W, Moore MJ, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004;279:3197-3201 (Pubitemid 38140552)
98. He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-81 • The first demonstration, to our knowledge, of the potent immunogenicity of the receptor-binding domain of the SCV.
99. Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis 2005;11:1016-1020 (Pubitemid 40880899)
100. He Y, Lu H, Siddiqui P, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-4915 (Pubitemid 40504575)
101. He Y, Zhu Q, Liu S, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005;334:74-82 (Pubitemid 40320736)
102. Chen Z, Zhang L, Qin C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005;79:2678-2688 (Pubitemid 40270546)
103. Yi CE, Ba L, Zhang L, et al. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol 2005;79:11638-11646 (Pubitemid 41279282)
104. Zhu ZY, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 2007;104:12123-12128 (Pubitemid 47185640)
105. Duan J, Yan X, Guo X, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 2005;333:186-193 (Pubitemid 40813463)
106. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4 • The identification of the receptor for SARS coronavirus is described. (Pubitemid 37490132)
107. Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-9 •• The identification of the natural reservoir of the SCV is described.
108. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102:14040-5 •• The identification of the natural reservoir of the SCV is described.
109. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309:1864-8 • Elucidation of the SCV S protein RBD and receptor ACE-2 complex structure is described.
110. Zhu Z, Dimitrov AS, Bossart KN, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006;80:891-9 •• The first, to our knowledge, identified human monoclonal antibodies against Hendra and Nipah viruses are described; they potently neutralize infectious virus. (Pubitemid 43062901)
111. Bonaparte MI, Dimitrov AS, Bossart KN, et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci USA 2005;102:10652-7 • The identification of Hendra and Nipah viruses receptor is described.
112. Negrete OA, Levroney EL, Aguilar HC, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 2005;436:401-5 • The identification of Hendra and Nipah viruses receptor is described. (Pubitemid 41059050)
113. Xu K, Rajashankar KR, Chan YP, et al. Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci USA 2008;105:9953-9958
114. Bowden TA, Aricescu AR, Gilbert RJC, et al. Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat Struct Mol Biol 2008;15:567-572 (Pubitemid 351799140)
115. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59 • The first, to our knowledge, crystal structure of HIV gp120 in complex with the CD4 receptor and an antibody. (Pubitemid 28289647)
116. Zhou TQ, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732-737 (Pubitemid 46279718)
117. Zhu Z, Bossart KN, Bishop KA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 2008;197:846-853